Pokhara Metropolitan City
Pokhara, Gandaki, Nepal
NCT Number: NCT06740708
The goal of this clinical trial is to evaluate whether a multifaceted community-based intervention, comprising 1) screening and lifestyle counseling by female community health volunteers (FCHVs); community health workers in Nepal, through home visits, and 2) regular Short Message Service (SMS) messages, can effectively reduce systolic blood pressure (SBP), lower fasting blood glucose, and increase smoking cessation rates among adults living in Pokhara with hypertension, type 2 diabetes, and smoking habits, respectively.
The main research questions are:
* Can FCHV home visits combined with regular mobile phone messages focused on blood pressure management reduce systolic blood pressure in adults with hypertension? * Can FCHV home visits combined with regular mobile phone messages focused on diabetes management lower fasting blood glucose levels in adults with type 2 diabetes? * Can FCHV home visits combined with regular mobile phone messages focused on smoking cessation increase the cessation rate among current smokers?
Researchers will compare the intervention group with a usual care group, which does not receive regular FCHV home visits for managing the three aforementioned risk factors or mobile phone messages.
This study is active but is not currently recruiting participants.
Notify Me40 year–75 year
All sexes
Interventional
Not applicable
Pokhara, Gandaki, Nepal
Background: Rapid globalization and urbanization continue to escalate the burden of non-communicable diseases (NCDs) across the world, disproportionally affecting low- and middle-income countries (LMICs). To date, trials have documented that task-sharing with community health workers (CHWs) can reduce systolic blood pressure and fasting blood glucose and achieve smoking cessation. However, most trials have been done in rural settings, and only focused on managing a single condition, such as hypertension. Furthermore, despite increasing evidence of the effectiveness from clinical trials, there is a lack of studies exploring best practices for 'how' to implement and sustain these interventions in LMICs.
Study Design: Type 2 hybrid effectiveness-implementation research study containing 1) a qualitative study, 2) open-label, two-armed, cluster randomized controlled trial (cRCT), and 3) implementation research plan. The details of the c-RCT only are presented below.
Settings: Pokhara Metropolitan City of Nepal. Pokhara is the second largest city in Nepal containing 33 administrative units called "wards". The investigators consider wards as clusters and randomize these 30 clusters (28 independent wards and 2 combined wards) into intervention and control groups in a 1:1 ratio.
Participants: Adults with ages between 40-75 having at least one of the following conditions:
i. BP≥140/90 mmHg at two separate measures, or ii. Under pharmacotherapy for hypertension
Intervention: Multifaceted intervention containing the following two components:
Control: Usual care in Pokhara Metropolitan City in Nepal, which does not include FCHV home visits for management of hypertension, diabetes, or smoking, and mobile phone messages.
Outcome: Changes in systolic blood pressure, fasting blood glucose, and smoking cessation at 6 months post randomization will be measured as primary outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months post randomization
Difference in systolic blood pressure change between the intervention and the control groups among participants enrolled as having hypertension.
Time frame: 6 months post randomization
Difference in fasting plasma glucose change between the intervention and the control groups among participants enrolled as having type 2 diabetes.
Time frame: 6 months post randomization
Participants who have not smoked for the past 30 days between the intervention and the control groups, among participants enrolled as current smokers.
Time frame: 6 months post randomization
Difference in diastolic blood pressure change between the intervention and the control groups among participants enrolled as having hypertension.
Time frame: 6 months post randomization
Difference in the proportion of those with BP<140/90 mmHg between the intervention and the control groups, among participants enrolled as having hypertension.
Time frame: 6 months post randomization
Difference in mean HbA1c between the intervention and the control groups, among participants enrolled as having type 2 diabetes.
Time frame: 6 months post randomization
Difference in mean weight between the intervention and the control groups, among participants enrolled as having type 2 diabetes.
Time frame: 6 months post randomization
Difference in mean total cholesterol levels between the intervention and the control groups, among participants with high total cholesterol (≥ 200 mg/dL) at baseline.
Time frame: 6 months post randomization
Difference in mean HDL levels between the intervention and the control groups, among participants with low HDL (< 40 mg/dL) at baseline.
Time frame: 6 months post randomization
Difference in mean LDL levels between the intervention and the control groups, among participants with high LDL (≥ 100 mg/dL) at baseline.
Time frame: 6 months post randomization
Difference in mean triglyceride levels between the intervention and the control groups, among participants with high triglyceride level (≥ 150 mg/dL) at baseline.
Time frame: 6 months post randomization
Difference in the proportion of those not missing a single anti-hypertensive pill over the past 1 week between the intervention and the control groups, among participants enrolled as having hypertension.
Time frame: 6 months post randomization
Difference in the proportion of those not missing a single hypoglycemic pill or injection over the past 1 week between the intervention and the control groups, among participants enrolled as having type 2 diabetes.
Time frame: 6 months post randomization
Difference in the proportion of those with a high FTND score (5-10) between the intervention and the control groups, among participants enrolled as current smokers. Higher means more dependence on nicotine.
Time frame: 6 months post randomization
Difference in the proportion of those who have not smoked for the past 7 days between the intervention and the control groups, among participants enrolled as current smokers.
Time frame: 6 months post randomization
Difference in the proportion of those taking 7 (if women) and 14 (if men) standard drinks over the past 1 week between the intervention and the control groups, among all participants.
Time frame: 6 months post randomization
Difference in the proportion of those taking 5 mg or less salt per day between the intervention and the control groups, among participants enrolled as having hypertension.
Time frame: 6 months post randomization
Difference in the proportion of those who had 3000 metabolic equivalents of tasks (MET) or more per week between the intervention and control groups, among participants enrolled as having hypertension and/or diabetes.
Time frame: 6 months post randomization
Difference in the proportion of those who consumed 5 or more servings of fruits and/or vegetables per day between the intervention and control groups, among participants enrolled as having hypertension and/or diabetes.
Johns Hopkins Bloomberg School of Public Health
Other
Acronym: SCALE NCD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06735859
Body Weight, Cardiovascular Diseases
Santos, São Paulo, Brazil
View Trial DetailsNCT06975501
Brain Diseases, Cardiovascular Diseases
Suzhou, Jiangsu, China
View Trial DetailsNCT06588127
Behavior, Cardiovascular Diseases
Lanzhou, Gansu, China
View Trial DetailsNCT06921356
Cardiovascular Diseases, Diabetes Mellitus
Baltimore, Maryland, United States
View Trial Details